Acorda Therapeutics

Share on Facebook Share on Twitter Email
Wikipedia on Answers.com:

Acorda Therapeutics

Top
Acorda Therapeutics Inc.
Type Public
Traded as NASDAQACOR FWBCDG
Industry Health care
Biotechnology
Founded 1995 (1995)[1]
Founder(s) Ron Cohen
Headquarters Hawthorne, New York, United States
Key people Ron Cohen
Andrew R. Blight
Products Zanaflex
Ampyra
Revenue increase US$292.2 Million (FY 2011)[2]
Operating income increase US$35.1 Million (FY 2011)[2]
Net income increase US$30.6 Million (FY 2011)[2]
Total assets increase US$379.5 Million (FY 2011)[2]
Total equity increase US$205.2 Million (FY 2011)[2]
Employees 328 (February, 2012) [2]
Website Acorda.com

Acorda Therapeutics (NASDAQACOR, FWBCDG) is a biotechnology company based in Hawthorne, New York. Acorda Therapeutics develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex and Ampyra in the United States.

Contents

History

Corporate governance

As of December 31, 2008 (2008 -12-31) the members of the board of directors of Acorda Therapeutics are:[4] Ron Cohen, Barry Greene, John Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, Ian F. Smith, and Wise Young.

Products

Products on the market

Products under development

References

External links

Hoover's



Post a question - any question - to the WikiAnswers community:

Copyrights: